Marcello Moccia, Ilaria Loperto, Laura Santoni, Silvia Masera, Giuseppina Affinito, Antonio Carotenuto, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino
{"title":"在多发性硬化症中延长纳他珠单抗间隔给药的医疗资源利用和成本。","authors":"Marcello Moccia, Ilaria Loperto, Laura Santoni, Silvia Masera, Giuseppina Affinito, Antonio Carotenuto, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino","doi":"10.2217/nmt-2021-0038","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aims:</b> Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. <b>Methods:</b> In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. <b>Results:</b> Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. <b>Conclusion:</b> Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"12 3","pages":"109-116"},"PeriodicalIF":2.3000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.\",\"authors\":\"Marcello Moccia, Ilaria Loperto, Laura Santoni, Silvia Masera, Giuseppina Affinito, Antonio Carotenuto, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino\",\"doi\":\"10.2217/nmt-2021-0038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aims:</b> Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. <b>Methods:</b> In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. <b>Results:</b> Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. <b>Conclusion:</b> Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":\"12 3\",\"pages\":\"109-116\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/nmt-2021-0038\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2021-0038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.
Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. Methods: In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. Results: Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. Conclusion: Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
